Gastroesophageal reflux disease and pregnancy: recommendations for safe treatment
Abstract
Gastroesophageal reflux disease (GERD) is common during pregnancy, affecting up to 80% of pregnant women. Treatment aims to relieve symptoms and not harm the fetus. Our objective is to provide guidance on the safe treatment of GERD in pregnancy. An electronic search of the English-language literature was performed in MEDLINE, PubMed, and Cochrane, to identify randomized controlled trials, observational studies, management recommendations, and reviews of GERD and its treatment during pregnancy. The search period was defined from 1992 to 2024. Treatment during pregnancy should be gradual, starting with lifestyle changes. If symptoms are severe, calcium-containing antacids or alginates should be started as the first pharmacological measure (grade A recommendation). If symptoms persist, sucralfate may be introduced (grade C recommendation), followed by a histamine-2 receptor antagonist (grade B recommendation). Proton pump inhibitors are reserved for women with intractable symptoms or complicated GERD; all are Food and Drug Administration category B drugs except omeprazole, which is category C (grade C recommendation). There are drugs that are contraindicated during pregnancy, and others that have not been thoroughly studied in this situation.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.